Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 539,730
  • Shares Outstanding, K 45,830
  • Annual Sales, $ 153,180 K
  • Annual Income, $ 33,370 K
  • 36-Month Beta 1.71
  • Price/Sales 2.54
  • Price/Book 3.73

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.40 +0.44%
on 01/19/17
14.79 -22.58%
on 12/20/16
-5.25 (-31.44%)
since 12/19/16
3-Month
10.60 +8.02%
on 11/02/16
17.55 -34.76%
on 11/30/16
-1.25 (-9.84%)
since 10/19/16
52-Week
9.59 +19.40%
on 03/17/16
17.55 -34.76%
on 11/30/16
-1.66 (-12.66%)
since 01/19/16

Most Recent Stories

More News
Drug Makers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Sucampo Pharma, and Pernix Therapeutics

Stock-Callers.com today evaluates the following Drug Manufacturers equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), and...

Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study

Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.

Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

Benitec Stock Up on Orphan Drug Status for BB-301 in EU

Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals

Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals

Key FDA Events to Watch Out for in Q1

Two important regulatory events scheduled in the first quarter of 2017.

4 Profitable Stocks with Amazingly High Returns

Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenue.

5 Top Ranked Stocks with Upgraded Broker Ratings to Buy Now

It's not an easy task for individual investors to choose profitable stocks on their own, given a number of fundamental and technical aspects that need to be considered. This is where expert advice comes...

Novartis to Conduct Trial on Obese, Type II Diabetes Patients

In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes....

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones...

See More

Support & Resistance

2nd Resistance Point 12.22
1st Resistance Point 11.83
Last Price 11.45
1st Support Level 11.23
2nd Support Level 11.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.